BCRX (BioCryst Pharmaceuticals, Inc.) Stock Financials & Earnings

BCRXBioCryst Pharmaceuticals, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$875M

Net Income (TTM)$264M

EPS (TTM)$1.20

Free Cash Flow (TTM)$328M

Gross Margin97.7%

Op. Margin39.0%

Net Margin30.2%

FCF Margin37.5%

P/S Ratio (TTM)2.1x

P/E Ratio (TTM)7.0x

YoY Rev Growth+94.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$69M	$68M	-$28M
Q2 23	$82M	$82M	-$21M
Q3 23	$87M	$86M	-$12M
Q4 23	$93M	$92M	-$43M
Q1 24	$93M	$91M	-$14M
Q2 24	$109M	$108M	$9M
Q3 24	$117M	$114M	$8M
Q4 24	$132M	$125M	-$5M
Q1 25	$146M	$141M	$21M
Q2 25	$163M	$161M	$30M
Q3 25	$159M	$157M	$30M
Q4 25	$407M	$397M	$260M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Collaborative and Other Research and Development	Product
Q3 23	$1M	$85M
Q1 24	$3M	$89M
Q2 24	$1M	$108M
Q3 24	$1M	$116M
Q1 25	$2M	$144M
Q2 25	$923K	$162M
Q3 25	$2M	$158M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$155M	$243M	$398M
Q2 23	$146M	$264M	$411M
Q3 23	$151M	$247M	$398M
Q4 23	$111M	$278M	$389M
Q1 24	$84M	$252M	$337M
Q2 24	$78M	$194M	$272M
Q3 24	$98M	$233M	$331M
Q4 24	$105M	$216M	$321M
Q1 25	$105M	$190M	$295M
Q2 25	$88M	$172M	$260M
Q3 25	$84M	$129M	$213M
Q4 25	$90M	$185M	$275M

Shares Outstanding

Revenue Per Employee

Revenue / Employee